Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study
Background We aimed to estimate XBB.1.5 vaccine effectiveness (VE) against COVID-19-related hospitalizations and deaths during BA.2.86/JN.1 predominance, among EU/EEA individuals with ≥65-years.Research design and methods We linked electronic health records to create historical cohorts in Belgium, D...
Saved in:
Main Authors: | Baltazar Nunes (Author), James Humphreys (Author), Nathalie Nicolay (Author), Toon Braeye (Author), Izaak Van Evercooren (Author), Christian Holm Hansen (Author), Ida Rask Moustsen-Helms (Author), Chiara Sacco (Author), Massimo Fabiani (Author), Jesús Castilla (Author), Iván Martínez-Baz (Author), Hinta Meijerink (Author), Ausenda Machado (Author), Patricia Soares (Author), Rickard Ljung (Author), Nicklas Pihlström (Author), Anthony Nardone (Author), Sabrina Bacci (Author), Susana Monge (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Severity of COVID-19 sub-lineages XBB/XBB 1.5/XBB1.16, EG.5.1. and JN.1. in England
by: Catherine Quinot, et al.
Published: (2024) -
Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection
by: Jin-Jin Chen, et al.
Published: (2023) -
Scientific American Supplement, No. 286, June 25, 1881
by: Various -
Microtitration of Rubella Virus in Monovalent Vaccinal Products
by: F Esna-Ashari, et al.
Published: (2011) -
Microtitration of Rubella Virus in Monovalent Vaccinal Products
by: F Esna-Ashari, et al.
Published: (2011)